Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

What this study is about

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL. Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally. Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Who can join (things the study team will check)

✅ You may be able to join if…

• Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL).
• Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country.
• The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.

🚫 You may not be able to join if…

• Any condition included in the contraindications section of the approved local epcoritamab label in the participating country.
• Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.

Where this trial is running

• Hospital Britanico de Buenos Aires /ID# 274419, Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina
• Hospital Universitario Austral /ID# 274393, Pilar, Buenos Aires, Argentina
• Instituto Alexander Fleming /ID# 277284, Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina
• Hospital Privado Universitario De Córdoba /ID# 274457, Córdoba, Córdoba Province, Argentina
• Hospital Italiano de Buenos Aires /ID# 274418, Buenos Aires, Argentina
• Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390, Buenos Aires, Argentina
• Nepean Cancer Centre, Nepean Hospital /ID# 277782, Kingswood, New South Wales, Australia
• Calvary Mater Newcastle /ID# 277783, Waratah, New South Wales, Australia
• Cabrini Hospital Malvern /ID# 277780, Malvern, Victoria, Australia
• Krankenhaus Der Barmherzigen Brueder Graz /ID# 273288, Graz, Styria, Austria
• Landeskrankenhaus Hochsteiermark, Standort Leoben /ID# 273266, Leoben, Styria, Austria
• Algemeen Ziekenhuis klina /ID# 273405, Brasschaat, Antwerpen, Belgium

+ 61 more sites.

Who to contact

Rebekah Taylor · (847) 937-8000 · rebekah.taylor@abbvie.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06830759.